Clinical trials: Stage IIIC1 Cervical Cancer FIGO 2018
Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the…
- Conditions
- Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma, Stage IIIA Cervical Cancer FIGO 2018
- Trial name
- NCT07061977
- Testing
- Biospecimen Collection, Brachytherapy, Carboplatin
- Where
- 344 sites in United States, Puerto Rico
- Volunteers
- 336 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB3 Cervical Cancer FIGO 2018
A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial
This phase IIA trial studies the effect of a vaccine (PDS0101) when given together with chemotherapy and radiation therapy (chemoradiation) in treating patients with stage IB3-IVA cervical cancer.
- Conditions
- Locally Advanced Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB3 Cervical Cancer FIGO 2018, Stage II Cervical Cancer FIGO 2018, Stage IIA Cervical Cancer FIGO 2018
- Trial name
- NCT04580771
- Testing
- Cisplatin, Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, Radiation Therapy
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Cervical Cancer by FIGO Stage 2018, Squamous Cell Carcinoma FIGO 2018 Stage IIIA, IIIB, IIIC1-IIIC2
Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer
The goal of this clinical trial is to learn if the combination of Pembrolizumab and Lenvatinib works to treat locally advanced cervical cancer in adults that will undergo primary chemoradiation and brachytherapy.
- Conditions
- Cervical Cancer by FIGO Stage 2018, Squamous Cell Carcinoma FIGO 2018 Stage IIIA, IIIB, IIIC1-IIIC2, Adenocarcinoma or Adeno-squamous Carcinoma Stage IB3-IIIC2
- Trial name
- NCT07368985
- Testing
- pembrolizumab and lenvatinib
- Where
- Netherlands
- Volunteers
- 87 people
- Sponsor
- Prof. Dr. Remi A. Nout
Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer
This study collects blood samples to determine if the DNA of HPV that causes cervical cancer can be detected in patients with cervical cancer that is new (primary), has come back (recurrent), or has spread to other places in the…
- Conditions
- Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Infiltrating Cervical Carcinoma, Metastatic Cervical Carcinoma
- Trial name
- NCT04574635
- Testing
- Biospecimen Collection
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
Stage IB Cervical Cancer FIGO 2018, Stage IB1 Cervical Cancer FIGO 2018
Patient-Informed Educational Intervention for the Improvement of Cervical Cancer Literacy
This study investigates the health literacy, cervical cancer knowledge, and radiation knowledge of patients with cervical cancer.
- Conditions
- Stage IB Cervical Cancer FIGO 2018, Stage IB1 Cervical Cancer FIGO 2018, Stage IB2 Cervical Cancer FIGO 2018, Stage IB3 Cervical Cancer FIGO 2018
- Trial name
- NCT05093712
- Testing
- Educational Intervention, Survey Administration
- Sponsor
- M.D. Anderson Cancer Center